At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 2,009 enrolled
Drug / intervention
3 months of dual antiplatelet therapy (DAPT) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
In Brief
A Phase 4 clinical trial evaluating 3 months of dual antiplatelet therapy (DAPT) and SYNERGY Stent System for Coronary Artery Disease. Completed, enrolled 2,009 participants across 110 sites in 7 countries.
Detailed Summary
The EVOLVE Short DAPT Study is a prospective, multicenter, single-arm study designed to assess the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with a SYNERGY Stent System.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesBrazil, Germany, Japan, Latvia, Sweden, Switzerland, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartFeb 2016
Primary CompletionJul 2019
TodayJul 2026
First PostedNov 16, 2015
Enrollment StartFeb 16, 2016
Primary CompletionJul 17, 2019
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 10.6 years ago
Interventions
3 months of dual antiplatelet therapy (DAPT)drug
3 months of P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) plus 15-months of aspirin
SYNERGY Stent Systemdevice
SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System